ArticleESMO open2025

Phase I trial of the combination of the pan-ErbB inhibitor neratinib and mTOR inhibitor everolimus in advanced cancer patients with ErbB family gene alterations.

S A Piha-Paul et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.